Cangrelor tetrasodium - CAS 163706-36-3
Catalog number: B0084-468043
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H21Cl2F3N5Na4O12P3S2
Molecular Weight:
864.274
COA:
Inquire
Targets:
P2Y Receptor
Description:
Cangrelor tetrasodium is an ATP analogue and acts as a reversible antagonist of P2Y12 receptor. Pretreatment with cangrelor significantly reduces blood clotting induced by ADP in a mouse model of pulmonary thromboembolism.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-468043 10 mg $199 In stock
Bulk Inquiry
Brife Description:
P2Y12 receptor antagonist
Synonyms:
Cangrelor Tetrasodium; AR-C69931MX; AR C69931MX; ARC69931MX; N6-(2-Methylthioethyl)-2-(3,3,3-trifluoropropylthio)-betagamma-dichloromethylene-ATP tetrasodium salt
MSDS:
Inquire
InChIKey:
COWWROCHWNGJHQ-OPKBHZIBSA-J
InChI:
InChI=1S/C17H25Cl2F3N5O12P3S2.4Na/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32;;;;/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32);;;;/q;4*+1/p-4/t8-,10-,11-,14-;;;;/m1..../s1
Canonical SMILES:
CSCCNC1=NC(=NC2=C1N=CN2C3C(C(C(O3)COP(=O)([O-])OP(=O)(C(P(=O)([O-])[O-])(Cl)Cl)[O-])O)O)SCCC(F)(F)F.[Na+].[Na+].[Na+].[Na+]
1.Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Goto S;Tamura N;Ishida H;Ruggeri ZM J Am Coll Cardiol. 2006 Jan 3;47(1):155-62. Epub 2005 Dec 15.
OBJECTIVES: ;We sought to evaluate the mechanisms that support the stability of platelet aggregates on a thrombogenic surface exposed to flowing blood.;BACKGROUND: ;Activation of the membrane glycoprotein (GP) IIb/IIIa--mediated in part through the P2Y1 and P2Y12 adenosine 5'-diphosphate (ADP) receptors--is necessary for platelet aggregation. Platelets in growing thrombi exhibit cyclic calcium signal, suggesting that sustained activation may be required for thrombus stability.;METHODS: ;Blood was perfused over type I collagen fibrils at the wall shear rate of 1,500 s(-1). Three-dimensional visualization of platelet thrombi was obtained in real time with confocal microscopy. The intracytoplasmic Ca2+ concentration ([Ca2+]i) was measured in fluo-3AM-loaded platelets.;RESULTS: ;The height of platelet thrombi in control blood was 13.5 +/- 3.3 microm after 6 min, and increased to 16.3 +/- 4.5 microm (n = 8) after an additional 6 min. In contrast, the height was reduced to 5.4 +/- 2.2 and 3.3 +/- 1.3 microm, respectively (p < 0.01, n = 8), when the blood used in the second 6-min perfusion contained a P2Y1 (MRS2179) or P2Y12 (AR-C69931MX) inhibitor. The [Ca2+]i of platelets within forming thrombi oscillated between 212 +/- 38 nmol/l and 924 +/- 458 nmol/l, with cycles lasting 4.
2.Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets.
Wei H;Malcor JM;Harper MT Sci Rep. 2018 Jul 3;8(1):9987. doi: 10.1038/s41598-018-28363-4.
Platelets protect the vascular system during damage or inflammation, but platelet activation can result in pathological thrombosis. Activated platelets release a variety of extracellular vesicles (EVs). EVs shed from the plasma membrane often expose phosphatidylserine (PS). These EVs are pro-thrombotic and increased in number in many cardiovascular and metabolic diseases. The mechanisms by which PS-exposing EVs are shed from activated platelets are not well characterised. Cholesterol-rich lipid rafts provide a platform for coordinating signalling through receptors and Ca;2+; channels in platelets. We show that cholesterol depletion with methyl-β-cyclodextrin or sequestration with filipin prevented the Ca;2+;-triggered release of PS-exposing EVs. Although calpain activity was required for release of PS-exposing, calpain-dependent cleavage of talin was not affected by cholesterol depletion. P2Y;12; and TPα, receptors for ADP and thromboxane A;2;, respectively, have been reported to be in platelet lipid rafts. However, the P2Y;12; antagonist, AR-C69931MX, or the cyclooxygenase inhibitor, aspirin, had no effect on A23187-induced release of PS-exposing EVs. Together, these data show that lipid rafts are required for release of PS-exposing EVs from platelets.
3.Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J;Klinkhardt U;Harder S Thromb Res. 2004;113(5):295-302.
BACKGROUND: ;In pharmacodynamic studies with antiplatelet agents, platelets are usually activated in vitro with single agonists (e.g., ADP) solely. We questioned whether differences occur between single and combined stimulation of platelets [involving the major thrombin-receptors, protease-activated receptors (PAR)1 and PAR4], and whether the pharmacodynamic response to common antiplatelet drugs vary when a combined stimulus is applied instead of a single agonist.;METHODS: ;We investigated the influence of different antiplatelet agents (aspirin [500 mg]) in vivo, the P2Y12-antagonist AR-C 69931MX (4 nM) and the GPII/IIIa-antagonist (abciximab ([5 microg/ml] in vitro) on the degranulation response (CD62) and expression of the activated GPIIb/IIIa-receptor (PAC-1) after stimulation with ADP (2 microM), collagen (4 microg/ml), a PAR1-activating peptide (3 microM TRAP) and a PAR4-activating peptide (200 microM AYPGKF) alone or in a combination of each two agonists by flow cytometry in healthy subjects.;RESULTS: ;(1) Combined activation of TRAP with AYPGKF resulted in synergistic CD62 and PAC-1 expression. Only AYPGKF but neither TRAP nor ADP acted synergistically with collagen. (2) AR-C 69931MX inhibited platelet degranulation (CD62) in all inducer combinations with ADP or the combination TRAP with AYPGKF.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products


CAS 163706-36-3 Cangrelor tetrasodium

Cangrelor tetrasodium
(CAS: 163706-36-3)

Cangrelor tetrasodium is an ATP analogue and acts as a reversible antagonist of P2Y12 receptor. Pretreatment with cangrelor significantly reduces blood clotting...

CAS 150322-43-3 Prasugrel

Prasugrel
(CAS: 150322-43-3)

Prasugrel is a thienopyridine prodrug that is converted by esterases to a receptor antagonist for purinergic P2Y12 receptors. The blockade of P2Y12 receptor act...

CAS 211427-08-6 Diquafosol tetrasodium

Diquafosol tetrasodium
(CAS: 211427-08-6)

Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.

CAS 711019-86-2 MRS 2578

MRS 2578
(CAS: 711019-86-2)

MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.

CAS 274693-27-5 Ticagrelor

Ticagrelor
(CAS: 274693-27-5)

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...

Prasugrel Maleic acid
(CAS: 389574-20-3)

Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.

CAS 367909-40-8 MRS 2279

MRS 2279
(CAS: 367909-40-8)

MRS 2279 is the first broadly applicable, selective and high affinity competitive antagonist radioligand for a P2Y receptor (Ki = 2.5 nM; IC50 = 51.6 nM).

CAS 1047980-83-5 MRS 2768 tetrasodium salt

MRS 2768 tetrasodium salt
(CAS: 1047980-83-5)

MRS 2768 tetrasodium salt is a selective P2Y2 agonist (EC50 = 1.89 μM), with no affinity for human P2Y4 or P2Y6 receptors.

Chemical Structure

CAS 163706-36-3 Cangrelor tetrasodium

Quick Inquiry

Verification code

Featured Items